in this issue
Pharma/fine chemicals roundup—2 January
8:24 AM MST | January 2, 2013 | By DEEPTI RAMESH
Mitsubishi Chemical to acquire pharma capsule manufacturer from Carlyle Group for $650 million
Mitsubishi Chemical and private equity firm The Carlyle Group (Washington) say that Mitsubishi will acquire Qualicaps (Yamatokoriyama, Japan) from Carlyle for ¥55.8 billion ($650 million). Qualicaps, which was established in 1965, develops, manufactures, and distributes capsules for pharmaceutical, and health, and nutrition products. Qualicaps' products include hard gelatin capsules, nongelatin hypromellose capsules, and pharmaceutical processing equipment. Qualicaps is the world’s second-largest provider of hard capsules to the global pharmaceutical industry, Carlyle says. Qualicaps has operations in Europe, Japan, and the United States, and the company recorded sales of ¥17.6 billion in 2011. The transaction is expected to close in March 2013.
Private equity firm acquires Cambridge Major for $212 million
Cambridge Major Laboratories (CML; Germantown, WI), a producer of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), and private equity firm American Capital (Bethesda, MD) say that American Capital has invested $212 million to acquire CML. CML was a portfolio company of private equity firm Arlington Capital Partners (Washington) prior to American Capital's investment. American Capital brings significant resources, relationships, and capital to fuel CML's growth, both organically and through acquisition, CML says.
Lonza completes sale of Arch performance urethanes and organics business to Monument Chemical
Lonza says it has completed the previously announced sale of the assets of it performance urethanes and organics business located at Brandenburg, KY, to Monument Chemical (Indianapolis). Financial terms of the deal were not disclosed. The two companies signed a deal for the sale in November 2012. The assets became a part of Lonza through the acquisition of Arch Chemicals (Norwalk, CT) in 2011. The sale enables Lonza to focus more on core activities, the company says.
Saltigo increases prices for 1,2,4-triazole and chloroformate products
Saltigo (Langenfeld, Germany), a Lanxess subsidiary, says it has increased its prices worldwide for the product group 1,2,4-triazole by €1.65/kg ($2.17/kg) effective 1 January 2013, because of increases in raw material, energy, and logistic costs. The intermediate is used, among other things, in the chemical synthesis of active pharmaceutical and agricultural ingredients. Saltigo will also increase prices by 10–20% across its chloroformate product portfolio effective 1 January 2013, in light of the continued increase in operational costs associated with the production, the company says.
BASF extends offer period for acquisition of Pronova BioPharma
BASF says it is extending, until 18 January 2013, the offer period for the company's acquisition of all of the issued and outstanding shares of Pronova BioPharma (Lysaker, Norway)—a pioneer in the fields of researching, developing, and manufacturing omega-3 fatty acids—for 12.50 Norwegian kroner/share ($2.25), or NK4.84 billion, in cash. The offer is conditional on BASF receiving acceptances for more than 90% of the total share capital of Pronova. BASF says that it has so far received acceptances from Pronova shareholders representing approximately 67.2% of the issued shares and votes in Pronova.
Lonza and Sartorius Stedim Biotech sign deal
Lonza says it has entered into a long-term global collaboration, supply, and distribution agreement with Sartorius Stedim Biotech (SSB; Aubagne, France), in the field of cell culture media. SSB is a leading provider of equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry, Lonza says. Cell culture media are growth substances and nutrients for cells or microorganisms, and are required in every biopharmaceutical manufacturing process.